Michiyo Urata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michiyo Urata has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Dongchon Kang2 shared publications
- Dongchon Kang
Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications Hiroko Iida
2 shared publicationsKumiko Watanabe
2 shared publications- Naotaka Hamasaki
Department of Clinical Chemistry, Faculty of Pharmaceutical Sciences, Natagaki International University, Nagasaki, Japan
2 shared publications Sachiko Hattori
2 shared publications
Latest Publications
- 1 February 2016
- Published by Elsevier in Brain and Development
- Vol. 38 (2) , 253-256
Fetal hydrocephalus and neonatal stroke as the first presentation of protein C deficiency
- 1 February 2016
- Published by Elsevier in Brain and Development
- Vol. 38 (2) , 253-256
Fetal hydrocephalus and neonatal stroke as the first presentation of protein C deficiency
- 1 January 2015
- Vol. 106 (1) , 16-22
[Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan].
Influenza virus has neuraminidase (NA), a surface protein with enzymatic activity that is essential for virus replication. Mutation may affect the effectiveness of NA inhibitors that are used for the treatment of influenza patients. In this study, we determined the NA gene sequences from the clinical isolates of influenza patients to examine the chronological genetic changes and the relation to drug susceptibility. For 96 A/H3N2 virus isolates the 50% inhibitory concentration (IC50) (48 each from the 2011-12 and 12-13 influenza seasons) was measured. RT-PCR was done with extracted viral RNA, followed by nucleotide sequencing. One putative amino acid mutation, D151N, was found in an NA activity-related cite in five of ninety-six tested isolate. The mutation did not affect the IC50 value. The mutations identified at amino acid positions 387 and 400 were statistically correlated with an increased IC50 value, although the change was less than ten times, suggesting no significant difference in the clinical effectiveness. A small number .of isolates showed mutation in the T and/or B cell epitope region of NA. No mutation that affected the IC50 value or effectiveness of NAIs was detected. Antigenic mutations of NA, which influence the selection of epidemic strains, were not determined. Continuous observation will be necessary to further clarify the genetic features of NA.
- 1 January 2015
- Vol. 106 (1) , 16-22
[Analysis of influenza A/H3N2 neuraminidase genes obtained from influenza patients in the 2011/12 and 2012/13 seasons in Japan].
Influenza virus has neuraminidase (NA), a surface protein with enzymatic activity that is essential for virus replication. Mutation may affect the effectiveness of NA inhibitors that are used for the treatment of influenza patients. In this study, we determined the NA gene sequences from the clinical isolates of influenza patients to examine the chronological genetic changes and the relation to drug susceptibility. For 96 A/H3N2 virus isolates the 50% inhibitory concentration (IC50) (48 each from the 2011-12 and 12-13 influenza seasons) was measured. RT-PCR was done with extracted viral RNA, followed by nucleotide sequencing. One putative amino acid mutation, D151N, was found in an NA activity-related cite in five of ninety-six tested isolate. The mutation did not affect the IC50 value. The mutations identified at amino acid positions 387 and 400 were statistically correlated with an increased IC50 value, although the change was less than ten times, suggesting no significant difference in the clinical effectiveness. A small number .of isolates showed mutation in the T and/or B cell epitope region of NA. No mutation that affected the IC50 value or effectiveness of NAIs was detected. Antigenic mutations of NA, which influence the selection of epidemic strains, were not determined. Continuous observation will be necessary to further clarify the genetic features of NA.
- 20 September 2013
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (4) , 763-764
A novel mutation in protein C gene (PROC) causing severe phenotype in neonatal period
Homozygous protein C deficiency is among rare causes of thrombophilia. Herein, we present a neonate with purpura fulminans, disseminated intravascular coagulation and severe intracranial hemorrhage who was found to have plasma protein C level of 4%. The molecular work‐up revealed a novel homozygous mutation of T903C (amino acid position Leu 270 Pro) located in a catalytic domain region of PROC gene. Asymptomatic course in patients with low but measurable levels of protein C levels has been reported, which is different than observed in our patient who had a very severe course despite plasma protein C level of 4%. Pediatr Blood Cancer 2014;61:763–764.
- 20 September 2013
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 61 (4) , 763-764
A novel mutation in protein C gene (PROC) causing severe phenotype in neonatal period
Homozygous protein C deficiency is among rare causes of thrombophilia. Herein, we present a neonate with purpura fulminans, disseminated intravascular coagulation and severe intracranial hemorrhage who was found to have plasma protein C level of 4%. The molecular work‐up revealed a novel homozygous mutation of T903C (amino acid position Leu 270 Pro) located in a catalytic domain region of PROC gene. Asymptomatic course in patients with low but measurable levels of protein C levels has been reported, which is different than observed in our patient who had a very severe course despite plasma protein C level of 4%. Pediatr Blood Cancer 2014;61:763–764.
- 1 December 2006
- Vol. 96 (6) , 854-5
Factor XII gene (F12) -4C/C polymorphism in combination with low protein S activity is associated with deep vein thrombosis.
- 1 December 2006
- Vol. 96 (6) , 854-5
Factor XII gene (F12) -4C/C polymorphism in combination with low protein S activity is associated with deep vein thrombosis.
- 1 January 2006
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 96 (12) , 854-855
Factor XII gene (F12) −4C/C polymorphism in combination with low protein S activity is associated with deep vein thrombosis
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren Zeitschriftenartikeln
- 1 January 2006
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 96 (12) , 854-855
Factor XII gene (F12) −4C/C polymorphism in combination with low protein S activity is associated with deep vein thrombosis
Schattauer GmbH - Verlag für Medizin und Naturwissenschaften ist ein renommierter Herausgeber von Fachbüchern, -zeitschriften und -software. Besuchen Sie unser Internetangebot mit Onlinezugang zu unseren Zeitschriftenartikeln